A carregar...
Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer
BACKGROUND: Gemcitabine (Gem) has limited clinical benefits in pancreatic ductal adenocarcinoma (PDAC). Sunitinib (Su) is a novel, multi-target receptor tyrosine kinase inhibitor that has antitumour activities. This study tested the benefits of combined gemcitabine and sunitinib in PDAC. METHODS: Ce...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3183443/ https://ncbi.nlm.nih.gov/pubmed/21843259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1477-2574.2011.00333.x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|